601 related articles for article (PubMed ID: 24871369)
1. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development.
Tu T; Budzinska MA; Maczurek AE; Cheng R; Di Bartolomeo A; Warner FJ; McCaughan GW; McLennan SV; Shackel NA
Int J Mol Sci; 2014 May; 15(6):9422-58. PubMed ID: 24871369
[TBL] [Abstract][Full Text] [Related]
2. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (Review).
Pan JH; Zhou H; Zhao XX; Ding H; Li W; Qin L; Pan YL
Int J Mol Med; 2018 Apr; 41(4):1809-1816. PubMed ID: 29328436
[TBL] [Abstract][Full Text] [Related]
3. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma.
Ruan Q; Wang H; Burke LJ; Bridle KR; Li X; Zhao CX; Crawford DHG; Roberts MS; Liang X
Int J Cancer; 2020 Sep; 147(6):1519-1527. PubMed ID: 32010970
[TBL] [Abstract][Full Text] [Related]
6. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever.
Carloni V; Luong TV; Rombouts K
Liver Int; 2014 Jul; 34(6):834-43. PubMed ID: 24397349
[TBL] [Abstract][Full Text] [Related]
7. The role of cytokines in hepatocellular carcinoma.
Budhu A; Wang XW
J Leukoc Biol; 2006 Dec; 80(6):1197-213. PubMed ID: 16946019
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils: Driving inflammation during the development of hepatocellular carcinoma.
Chen H; Zhou XH; Li JR; Zheng TH; Yao FB; Gao B; Xue TC
Cancer Lett; 2021 Dec; 522():22-31. PubMed ID: 34517084
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
[TBL] [Abstract][Full Text] [Related]
11. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
12. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
13. Role of innate immunity in the development of hepatocellular carcinoma.
Aravalli RN
World J Gastroenterol; 2013 Nov; 19(43):7500-14. PubMed ID: 24282342
[TBL] [Abstract][Full Text] [Related]
14. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
15. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
16. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
17. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis
Qiu LW; Liu YF; Cao XQ; Wang Y; Cui XH; Ye X; Huang SW; Xie HJ; Zhang HJ
World J Gastroenterol; 2020 May; 26(18):2126-2137. PubMed ID: 32476780
[TBL] [Abstract][Full Text] [Related]
18. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression.
Wu Q; Zhou L; Lv D; Zhu X; Tang H
J Hematol Oncol; 2019 May; 12(1):53. PubMed ID: 31142326
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in the emerging role of exosome in hepatocellular carcinoma.
Abudoureyimu M; Zhou H; Zhi Y; Wang T; Feng B; Wang R; Chu X
Cell Prolif; 2019 Mar; 52(2):e12541. PubMed ID: 30397975
[TBL] [Abstract][Full Text] [Related]
20. Extracellular vesicles-derived OncomiRs mediate communication between cancer cells and cancer-associated hepatic stellate cells in hepatocellular carcinoma microenvironment.
Li J; Yan Y; Ang L; Li X; Liu C; Sun B; Lin X; Peng Z; Zhang X; Zhang Q; Wu H; Zhao M; Su C
Carcinogenesis; 2020 Apr; 41(2):223-234. PubMed ID: 31140556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
